P. Wolkenstein

21.5k total citations · 4 hit papers
361 papers, 12.6k citations indexed

About

P. Wolkenstein is a scholar working on Neurology, Dermatology and Rheumatology. According to data from OpenAlex, P. Wolkenstein has authored 361 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Neurology, 113 papers in Dermatology and 111 papers in Rheumatology. Recurrent topics in P. Wolkenstein's work include Neurofibromatosis and Schwannoma Cases (121 papers), Drug-Induced Adverse Reactions (82 papers) and Autoimmune Bullous Skin Diseases (52 papers). P. Wolkenstein is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (121 papers), Drug-Induced Adverse Reactions (82 papers) and Autoimmune Bullous Skin Diseases (52 papers). P. Wolkenstein collaborates with scholars based in France, United States and Germany. P. Wolkenstein's co-authors include J. Revuz, Sylvie Bastuji‐Garin, L. Valeyrie‐Allanore, O. Chosidow, Jean‐Claude Roujeau, Nicolás Ortonne, T.A. Duong, J Zeller, F. Poli and M. Bertocchi and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

P. Wolkenstein

329 papers receiving 12.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis

2000 772 citations P. Wolkenstein et al. Journal of Investigative Dermatology profile →
Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies

2008 465 citations P. Wolkenstein et al. profile →
Severe cutaneous adverse reactions to drugs

2017 244 citations T.A. Duong, L. Valeyrie‐Allanore et al. profile →
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

2022 99 citations P. Wolkenstein, É. Sbidian et al. profile →

Peers

Countries citing papers authored by P. Wolkenstein

Since Specialization

Citations

This map shows the geographic impact of P. Wolkenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Wolkenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Wolkenstein more than expected).

Fields of papers citing papers by P. Wolkenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Wolkenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Wolkenstein. The network helps show where P. Wolkenstein may publish in the future.

Co-authorship network of co-authors of P. Wolkenstein

This figure shows the co-authorship network connecting the top 25 collaborators of P. Wolkenstein. A scholar is included among the top collaborators of P. Wolkenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Wolkenstein. P. Wolkenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: How to Improve the Evaluation of Therapeutic Strategies 2025 ·Journal of Investigative Dermatology ·S. Oro, Lars E. French, P. Wolkenstein	0
2	Diagnosing and Managing Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017–2023 2025 ·Journal of Investigative Dermatology ·S. Oro, (unknown), (unknown), J. Gueudry, (unknown), H. Assier, P. Wolkenstein, Nicolas de Prost, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
3	Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas 2024 ·Neuro-Oncology Practice ·Amedeo A. Azizi, Darren Hargrave, (unknown), P. Wolkenstein, Thorsten Rosenbaum, Claudia Santoro, (unknown), Thomas Pletschko, Paolo A. Ascierto, S.P. Hector	5
4	Maintenance treatment of pemphigus with rituximab in real life: A single-center study of 50 patients 2024 ·Annales de Dermatologie et de Vénéréologie ·(unknown), (unknown), (unknown), (unknown), (unknown), Thibaut Belmondo, P. Wolkenstein, S. Oro	1
5	Prenatal diagnosis for neurofibromatosis type 1 and the pitfalls of germline mosaics 2024 ·npj Genomic Medicine ·(unknown), Dominique Vidaud, (unknown), (unknown), (unknown), (unknown), (unknown), Ingrid Laurendeau, (unknown), (unknown), Benoît Funalot, P. Wolkenstein, Michel Vidaud, Alice Goldenberg, Fanny Morice‐Picard, Djihad Hadjadj, Béatrice Parfait, Éric Pasmant	2
6	Whole-Body Positron Emission Tomography with 18F-Fluorodeoxyglucose/Magnetic Resonance Imaging as a Screening Tool for the Detection of Malignant Transformation in Individuals with Neurofibromatosis Type 1 2024 ·Journal of Investigative Dermatology ·L. Fertitta, (unknown), O. Zehou, Christina Bergqvist, S. Ferkal, (unknown), Lionel Lerman, Sebastien Mulé, Alain Luciani, Blanche Bapst, Khaled Ezzedine, Nicolás Ortonne, Emmanuel Itti, P. Wolkenstein	3
7	cNF-Skindex in Adults Living with Neurofibromatosis 1: Severity Strata in France and Validation in United States Adults 2023 ·Journal of Investigative Dermatology ·L. Fertitta, Kavita Y. Sarin, Christina Bergqvist, (unknown), (unknown), (unknown), (unknown), (unknown), S. Ferkal, Philippe Ravaud, (unknown), Jaishri O. Blakeley, Carlos G. Romo, Khaled Ezzedine, P. Wolkenstein	2
8	French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study 2023 ·European Journal of Medical Genetics ·P. Wolkenstein, Yves Chaix, (unknown), Mona Amini‐Adlé, S. Barbarot, (unknown), (unknown), (unknown), Isabelle Aerts	1
9	Current and Emerging Imaging Techniques for Neurofibromatosis Type 1–Associated Cutaneous Neurofibromas 2023 ·Journal of Investigative Dermatology ·(unknown), Jaishri O. Blakeley, Ina Ly, Yemima Berman, (unknown), P. Wolkenstein, Christina Bergqvist, Wangcun Jia, Thomas E. Milner, Nitesh Katta, Anthony J. Durkin, Gordon T. Kennedy, Rebecca Rowland, Carlos G. Romo, Jane Fleming, Kristen M. Kelly	6
10	Erythema multiforme associated with anti‐plakin antibodies: a multicentric retrospective case series 2022 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), V. Descamps, François Chasset, T. Mahévas, Isabelle Bourgault‐Villada, P. Wolkenstein, Sylvie Chollet‐Martin, S. Oro, S. Grootenboer‐Mignot	5
11	ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis 2022 ·European Journal of Human Genetics ·D. Gareth Evans, (unknown), David Pang, (unknown), (unknown), Nicolas Champollion, P. Wolkenstein, Nick Thomas, Rosalie E. Ferner, Michel Kalamarides, Matthieu Peyre, Laura Papi, Eric Legius, Juan Luís Becerra, Andrew T. King, Chris Duff, Stavros Stivaros, Ignacio Blanco	16
12	Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts 2021 ·Dermatology ·(unknown), Laëtitia Penso, Viet-Thi Tran, Claire Hotz, Philippe Guillem, A. Villani, Pierre Perrot, (unknown), Eric Jacquet, Aude Nassif, H. Bachelez, P. Wolkenstein, M. Beylot‐Barry, M.‐A. Richard, Philippe Ravaud, M. Viguier, É. Sbidian	5
13	Which patients present to dermatologic emergencies? A survey on 1561 patients 2021 ·Journal of the European Academy of Dermatology and Venereology ·Charbel Skayem, (unknown), L. Fardet, Khaled Ezzedine, (unknown), S. Oro, P. Wolkenstein, O. Chosidow, T.A. Duong	0
14	Lymphoproliferative malignancies in patients with neurofibromatosis 1 2021 ·Orphanet Journal of Rare Diseases ·Christina Bergqvist, F. Hémery, (unknown), S. Ferkal, P. Wolkenstein	7
15	Neurofibromatosis I and multiple sclerosis 2020 ·Orphanet Journal of Rare Diseases ·Christina Bergqvist, F. Hémery, S. Ferkal, P. Wolkenstein	8
16	Chronic pain: a long‐term sequela of epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) – prevalence, clinical characteristics and risk factors 2020 ·Journal of the European Academy of Dermatology and Venereology ·Jean‐Pascal Lefaucheur, L. Valeyrie‐Allanore, Sophie Ng Wing Tin, (unknown), A. Colin, (unknown), Nicolas de Prost, P. Wolkenstein, S. Oro, O. Chosidow	9
17	Segmental schwannomatosis: characteristics in 12 patients 2019 ·Orphanet Journal of Rare Diseases ·(unknown), Béatrice Parfait, S. Ferkal, (unknown), P. Wolkenstein, J. Mazereeuw‐Hautier	17
18	Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells 2018 ·Cancer Discovery ·Katarzyna J. Radomska, Fanny Coulpier, Aurélie Gresset, Alain Schmitt, (unknown), Sophie Lemoine, P. Wolkenstein, Jean‐Michel Vallat, Patrick Charnay, Piotr Topilko	56
19	Pemphigus et herpès : enquête multicentrique et revue de la littérature 2018 ·Annales de Dermatologie et de Vénéréologie ·(unknown), (unknown), P. Bernard, (unknown), Jean François Meritet, P. Wolkenstein, N. Dupin, P. Joly, O. Chosidow, S. Oro	1
20	Microarray-Based Identification of Tenascin C and Tenascin XB , Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1 2007 ·Clinical Cancer Research ·Pascale Lévy, Hugues Ripoche, Ingrid Laurendeau, Vladimir Lazar, Nicolás Ortonne, Béatrice Parfait, Karen Leroy, Janine Wechsler, Isabelle Salmon, P. Wolkenstein, Philippe Dessen, Michel Vidaud, Dominique Vidaud, Ivan Bièche	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact